TRV GP II, LLC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.0%.

Quarter-by-quarter ownership
TRV GP II, LLC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$1,340,000
-67.2%
572,829
-57.5%
100.00%
+13.1%
Q2 2022$4,084,000
-55.4%
1,347,8290.0%88.46%
-5.3%
Q1 2022$9,152,000
-59.4%
1,347,829
-50.0%
93.42%
+0.3%
Q4 2021$22,527,000
+12.4%
2,697,8290.0%93.16%
+4.9%
Q3 2021$20,045,000
-33.7%
2,697,829
-39.3%
88.84%
-0.5%
Q2 2021$30,245,000
-54.7%
4,447,829
-31.6%
89.29%
+111.6%
Q1 2021$66,759,000
+3.7%
6,500,349
-29.3%
42.19%
-6.0%
Q4 2020$64,402,000
-22.9%
9,200,349
-10.1%
44.86%
-17.2%
Q3 2020$83,480,000
+18.3%
10,230,3490.0%54.19%
+3.8%
Q2 2020$70,589,000
+45.3%
10,230,3490.0%52.18%
-0.0%
Q1 2020$48,594,000
-45.6%
10,230,3490.0%52.19%
-43.4%
Q4 2019$89,311,000
+162.2%
10,230,3490.0%92.14%
+21.9%
Q3 2019$34,067,000
-32.7%
10,230,3490.0%75.60%
-7.4%
Q2 2019$50,640,000
-20.2%
10,230,3490.0%81.68%
+97.5%
Q1 2019$63,428,000
+84.0%
10,230,3490.0%41.36%
+20.7%
Q4 2018$34,476,000
-48.2%
10,230,3490.0%34.26%
-12.2%
Q3 2018$66,497,000
-15.1%
10,230,3490.0%39.04%
-12.1%
Q2 2018$78,364,000
-65.7%
10,230,3490.0%44.43%
+3.7%
Q1 2018$228,648,000
+75.3%
10,230,3490.0%42.85%
+82.4%
Q4 2017$130,437,00010,230,34923.49%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
TRV GP II, LLC 1,347,829$9,152,00093.42%
Ally Bridge Group (NY) LLC 550,000$3,735,0002.77%
ACUTA CAPITAL PARTNERS, LLC 813,500$5,524,0002.58%
TRV GP III, LLC 1,148,780$7,800,0002.12%
Deep Track Capital, LP 4,259,653$28,923,0001.86%
Logos Global Management LP 1,400,000$9,506,0001.23%
PFM Health Sciences, LP 3,972,868$26,976,0001.01%
Sofinnova Investments, Inc. 1,481,219$10,057,0000.76%
SILVERARC CAPITAL MANAGEMENT, LLC 248,347$1,686,0000.70%
RTW INVESTMENTS, LP 4,680,412$31,780,0000.66%
View complete list of JOUNCE THERAPEUTICS INC shareholders